{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=41",
    "query": {
      "condition": "Deformity; Skin",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 1851,
    "total_pages": 186,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Deformity%3B+Skin&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T23:25:36.717Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05891119",
      "title": "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Caffeine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Metoprolol",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Vitamin K",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        },
        {
          "name": "Rocatinlimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-06-03",
      "completion_date": "2025-02-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 7,
      "location_summary": "North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more",
      "locations": [
        {
          "city": "North Hollywood",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Dilworth",
          "state": "Minnesota"
        },
        {
          "city": "Camp Hill",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891119"
    },
    {
      "nct_id": "NCT01746511",
      "title": "Glycerin Suppositories to Reduce Jaundice in Premature Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Idiopathic Hyperbilirubinemia",
        "Neonatal Hyperbilirubinemia",
        "Prematurity"
      ],
      "interventions": [
        {
          "name": "Phototherapy",
          "type": "PROCEDURE"
        },
        {
          "name": "glycerin suppository",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Weeks",
        "maximum_age": "35 Weeks",
        "sex": "ALL",
        "summary": "30 Weeks to 35 Weeks"
      },
      "enrollment_count": 79,
      "start_date": "2012-07",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-12-09",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01746511"
    },
    {
      "nct_id": "NCT01873911",
      "title": "Neurobehavioral Phenotypes in MPS III",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sanfilippo Syndrome Type A",
        "Sanfilippo Syndrome Type B",
        "Hurler Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "2 Years to 12 Years"
      },
      "enrollment_count": 30,
      "start_date": "2010-12",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2019-11-01",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873911"
    },
    {
      "nct_id": "NCT06974877",
      "title": "Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cryopyrin-Associated Periodic Syndromes",
        "Amyloidosis"
      ],
      "interventions": [
        {
          "name": "124I AT-01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-09-10",
      "completion_date": "2032-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06974877"
    },
    {
      "nct_id": "NCT03627767",
      "title": "Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dermatitis",
        "Dermatitis, Atopic",
        "Eczema",
        "Skin Diseases",
        "Skin Diseases, Genetic",
        "Genetic Diseases, Inborn",
        "Skin Diseases, Eczematous",
        "Hypersensitivity",
        "Hypersensitivity, Immediate",
        "Immune System Diseases"
      ],
      "interventions": [
        {
          "name": "PF-04965842 100 mg",
          "type": "DRUG"
        },
        {
          "name": "PF-04965842 200 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1235,
      "start_date": "2018-06-11",
      "completion_date": "2020-10-07",
      "has_results": true,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 52,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Fremont, California + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03627767"
    },
    {
      "nct_id": "NCT01697319",
      "title": "Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mucopolysaccharidosis IVA",
        "Morquio A Syndrome",
        "MPS IVA"
      ],
      "interventions": [
        {
          "name": "BMN 110",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2012-08",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2016-01-12",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01697319"
    },
    {
      "nct_id": "NCT05704738",
      "title": "A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Rocatinlimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 532,
      "start_date": "2023-04-20",
      "completion_date": "2025-11-25",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 98,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 84 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05704738"
    },
    {
      "nct_id": "NCT07734415",
      "title": "Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Atopic Dermatitis Eczema",
        "Eczema"
      ],
      "interventions": [
        {
          "name": "IMG-007",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inmagene LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 400,
      "start_date": "2026-06-05",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-07-29",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 16,
      "location_summary": "Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rolling Meadows",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07734415"
    },
    {
      "nct_id": "NCT03536143",
      "title": "A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Topical beremagene geperpavec",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo gel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Krystal Biotech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-05-06",
      "completion_date": "2019-11-01",
      "has_results": true,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03536143"
    },
    {
      "nct_id": "NCT05932732",
      "title": "Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Cutis Laxa Facialis",
        "Xeroderma"
      ],
      "interventions": [
        {
          "name": "HydraFacial Syndeo System",
          "type": "DEVICE"
        },
        {
          "name": "ReGen-GF",
          "type": "DRUG"
        },
        {
          "name": "HydraFacial Elite MD System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Austin Institute for Clinical Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "30 Years to 55 Years"
      },
      "enrollment_count": 27,
      "start_date": "2023-11-20",
      "completion_date": "2024-10-09",
      "has_results": false,
      "last_update_posted_date": "2024-10-24",
      "last_synced_at": "2026-10-28T23:25:36.717Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • Pflugerville, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Pflugerville",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05932732"
    }
  ]
}